Alaunos Therapeutics Inc. surged as positive clinical trial progress boosted investor optimism, and stocks have been trading up by 13.74 percent.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Alaunos Therapeutics completed the Velaris Therapeutics acquisition, adding ActRII‑Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
- The company raised about $350M in a concurrent private placement, extending its cash runway into 2029 and funding several programs through proof‑of‑concept and early regulatory filings.
- Shares of TCRT ripped between roughly 126% and 225% on extremely heavy trading volume after the Velaris deal and financing hit the tape.
- Fairmount Funds disclosed a 19.99% stake in Alaunos Therapeutics and aims to secure four of five board seats, pending shareholder approval.
Live Update At 08:32:33 EDT: On Monday, October 19, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 13.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT has turned into a full‑blown momentum story, but the financials still look like an early‑stage biotech. Alaunos Therapeutics generated only about $5,000 in revenue, with a price‑to‑sales ratio near 957. That tells traders the market is paying up for the story and the pipeline, not the current business.
Margins are deeply negative. Pretax profit margin sits around -3,347.5%, and returns on equity and assets are sharply below zero. TCRT is burning cash, posting about -$300,000 in free cash flow for the latest quarter, and ending with just $124,000 in cash on the balance sheet before the new $350M raise.
Liquidity was tight before the deal: a current ratio of 0.8 and working capital of -$198,000 showed pressure. That’s why the Alaunos Therapeutics financing matters so much. For traders, the extended runway into 2029 changes the bankruptcy risk narrative and sets up multi‑year catalyst windows.
More Breaking News
- SOFI Stock Slips As Analyst Cut And Insider Sale Hit Sentiment
- Diamondback Energy Stock Climbs as Wall Street Lifts Price Targets
- SOFI Stock Slips As Price Target Cut Adds $1B Headwind Warning
- XLAB Stock Jumps As NVIDIA GPU Contract Ignites AI Hype
On the chart, TCRT exploded from sub‑$1 levels on 2026/10/12 to a $4.40 intraday high on 2026/10/14 before pulling back into the mid‑$2s. That’s a textbook parabolic spike plus retrace, which short‑term traders know can offer both massive opportunity and real trap risk.
Why Traders Are Watching TCRT Now
This week’s story is all about catalysts. Alaunos Therapeutics, trading under ticker TCRT, closed its acquisition of Velaris Therapeutics and instantly reshaped its profile. By adding ActRII‑Fc ligand traps and other biologics for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases, Alaunos moved from a tiny, struggling biotech into a pipeline‑driven speculative name.
The $350M private placement tied to the deal is the fuel behind the fire. TCRT placed Series C non‑voting convertible preferred stock, a structure that brings in serious capital but sits above common shares in the stack. That cash is expected to fund operations into 2029 and push several candidates, including lead PAH asset VLR199, through proof‑of‑concept and early regulatory milestones. Traders in TCRT are effectively betting that at least one of these programs delivers data strong enough to reprice the stock again.
The market reaction has been violent. Alaunos Therapeutics shares initially spiked about 126% on the Velaris and funding news, then surged as much as roughly 225% on extremely heavy volume as the story spread. For TCRT, that type of move signals a shift from forgotten micro‑cap to front‑page momentum ticker on many scanners.
Then came another spark: SEC filings showed Fairmount Funds taking a 19.99% stake in Alaunos Therapeutics and signaling plans to grab four of five board seats, subject to shareholder approval. Activist‑style pressure like this often leads to faster strategic decisions, which short‑term traders in TCRT typically love because it increases the flow of news and potential catalysts.
Conclusion
TCRT is now the kind of chart that grabs every momentum trader’s eye. Alaunos Therapeutics went from a sub‑$1 stock with limited cash to a biotech sitting on a $350M war chest, a fresh pipeline from Velaris Therapeutics, and a flagship PAH program in VLR199 that the market will track closely. The extended runway into 2029 gives Alaunos Therapeutics time to execute, but it also keeps TCRT in play as a catalyst‑driven trading vehicle for years.
The price action tells the story. A run from under $1 to a $4.40 high in two sessions, followed by a pullback into the mid‑$2s, is classic parabolic behavior. Traders in TCRT should expect volatility to stay high as early longs lock in gains, late chasers get squeezed, and shorts test the conviction behind the news.
Governance is now part of the setup. Fairmount Funds pushing for control of four out of five board seats at Alaunos Therapeutics suggests TCRT may see sharper strategic moves, whether that means aggressive development, partnerships, or more financial engineering. Each step can become a new trading catalyst.
For active traders, the mission with TCRT is simple: respect the volatility and trade the catalysts, not the hype. As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. As Tim Sykes likes to remind his students, “The pattern is predictable, but the outcome never is—your job is to manage risk first, profits second.” This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.